Joseph M. Leone
Director of Finance/CFO at RMH Franchise Holdings, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mark Martinelli | M | 64 |
Baruch College Fund
| 14 years |
M. Reiss | M | 77 |
Baruch College Fund
| - |
Michael Roth | M | 78 |
Baruch College Fund
| - |
Thomas Shara | M | 66 |
Ramapo College Foundation
| - |
Eric Kirsch | M | 63 |
Baruch College Fund
| - |
Leon Shivamber | M | - |
Baruch College Fund
| - |
Francis J. Rodriguez | M | - |
Ramapo College Foundation
| 20 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey M. Peek | M | 76 | 7 years | |
Peter Joseph Tobin | M | 79 | 33 years | |
Kenneth A. Brause | M | 59 | 11 years | |
Albert Gamper | M | 82 | 17 years | |
Kelley J. Gipson | F | 62 | - | |
Steven C. Berger | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 years |
Benton E. Sergi | M | 62 | 5 years | |
Ben Marzouk | M | - | 7 years | |
Marianne Miller Parrs | F | 79 | 15 years | |
Gerald Rosenfeld | M | 77 | 12 years | |
R. Brad Oates | M | 70 | 13 years | |
John Thain | M | 69 | 6 years | |
Seymour Sternberg | M | 80 | 11 years | |
Richard Rosenblum | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 years |
John F. Daly | M | 75 | 16 years | |
William M. Freeman | M | 71 | 19 years | |
Michael Embler | M | 60 | 7 years | |
Lawrence A. Marsiello | M | 73 | - | |
Robert J. Ingato | M | 62 | 17 years | |
John Ryan | M | 79 | 19 years | |
Gregory K. Park | M | - | 6 years | |
Alexander T. Mason | M | 72 | 2 years | |
Conrad Vlak | M | - | - | |
Susan Bihler | F | - | - | |
Bruce Quinn | M | - | - | |
Mike M. Goldberg | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Christopher H. Shays | M | 78 | - | |
Glenn Votek | M | 65 | 14 years | |
Tim J. Eichenlaub | M | - | 3 years | |
Nancy Foster | F | 62 | 2 years | |
James J. Duffy | M | 69 | 4 years | |
Paul Drury | M | - | - | |
Robert T. Bielinski | M | - | 8 years | |
Joseph F. Nemia | M | - | - | |
Michael Baresich | M | - | 7 years | |
Catherine Jennifer Chiavetta | F | - | 4 years | |
Raemon Polk | M | - |
KPMG Peat Marwick Ltd.
| 15 years |
Aaron Kitlowski | M | 50 | 6 years | |
Sherrese Soares | F | 47 | 4 years | |
John J. Smith | M | - | 10 years | |
Edward K. Sperling | M | 59 | 12 years | |
Gregory Sting | M | 61 | 4 years | |
Matthew Beaman | M | - | 4 years | |
Barbara A. Callahan | F | - | 23 years | |
W. Taylor Kamp | M | - | - | |
Brian Head | M | - | 6 years | |
Allen Good | M | - | 1 years | |
Frank Marsicano | M | - | 4 years | |
Edward M. Topham | M | 66 |
KPMG Peat Marwick Ltd.
| 2 years |
Duane Wesley Hosang | M | - | 3 years | |
Paul G. Petrylak | M | - | - | |
Jeffrey Bardos | M | - | - | |
Daniel C. de Brauwere | M | 68 | 3 years | |
Colleen M. Brown | F | 64 |
KPMG Peat Marwick Ltd.
| 4 years |
Diana N. McElroy | F | - | - | |
Scott E. Herbst | M | - | 4 years | |
Daniel B. Powell | M | - |
KPMG Peat Marwick Ltd.
| 13 years |
Terry Kelleher | F | - | 6 years | |
Gary C. Butler | M | 77 | 5 years | |
Timothy Ring | M | 66 | 4 years | |
Jeffrey Sklar | M | 61 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Kenneth D. Pearsen | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
James Hudak | M | 60 | 11 years | |
Peter J. Connolly | M | 58 | - | |
Robert V. O'Connor | M | 61 | 6 years | |
Tom Kean | M | 88 | - | |
Scott Anderson | M | 66 | 1 years | |
John I. Hill | M | 70 |
KPMG Peat Marwick Ltd.
| 12 years |
William J. Taylor | M | 72 | 19 years | |
B. Thomas Mueller | M | 76 |
KPMG Peat Marwick Ltd.
| 8 years |
Fred W. Hill | M | 73 | 5 years | |
Thomas Hallman | M | 71 | 12 years | |
Henry Y. L. Toh | M | 66 |
KPMG Peat Marwick Ltd.
| 12 years |
Anthea Disney | F | 79 | 3 years | |
Michael Carpenter | M | 75 | - | |
Ilya Klets | M | - | 1 years | |
Colby W. Collier | M | - | 16 years | |
David G. Tahan | M | - | - | |
Andreas Skibiel | M | - | 12 years | |
Christopher Layden | M | - | 11 years | |
Robert Golding | M | - | - | |
Francis P. Reardon | M | - |
KPMG Peat Marwick Ltd.
| - |
Arthur B. Newman | M | 80 | 1 years | |
Paul J. Laud | M | - | 21 years | |
Anthony P. Terracciano | M | 85 | - | |
David Sharpless | M | 74 | 1 years | |
Thomas Lyles | M | - |
KPMG Peat Marwick Ltd.
| - |
Pian Tee Hong | M | 79 |
KPMG Peat Marwick Ltd.
| - |
Daniel Ninivaggi | M | 59 | 2 years | |
Nachum Stein | M | 75 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
James Scott McDonald | M | 70 | - | |
Walter Owens | M | 63 | 3 years | |
Reyna Vince P | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 90 | 90.00% |
United Kingdom | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joseph M. Leone
- Personal Network